◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › O › ORKA

Oruka Therapeutics, Inc. (ORKA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-15

Oruka Therapeutics, Inc. (ORKA) operates in the BIOTECHNOLOGY industry and is headquartered in Menlo Park, United States with about 68 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, ORKA reported $0M in revenue and ($105M) in net income.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Interactive charts & full statements →

ORKA Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue—$0M—————————————————$47M$4M
Gross Profit—$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M($3M)$0M——$45M$1M
Gross Margin %———————————————————95.0%18.2%
Operating Income (EBIT)($155M)($122M)($88M)($7M)($10M)($19M)($10M)($6M)($8M)($19M)($17M)($11M)($10M)($7M)($4M)($7M)($9M)($23M)($19M)($17M)($141M)
Operating Margin %———————————————————-35.3%-3615.6%
Net Income($133M)($105M)($84M)($5M)($10M)($19M)($10M)($5M)($8M)($18M)($16M)($11M)($10M)($7M)($4M)($5M)($8M)($9M)($19M)($12M)($133M)
Net Margin %———————————————————-26.2%-3415.1%
EBITDA($142M)($105M)($82M)($5M)($10M)($19M)($10M)($6M)($8M)($19M)($16M)($11M)($10M)($7M)($4M)($5M)($8M)($11M)($19M)($10M)($129M)
Earnings Per Share (EPS)$-2.46$-2.31$-4.99$-0.37$-0.69$-1.39$-2.07$-49.79$-123.73$-382.87$-391.73$-393.07$-714.58$-1,215.88$-2,938.78$-4,849.91$-8,979.90$-11,688.71$-4,648,564.59$-41,848.68$-468,233.59
Shares Outstanding (M)63M46M17M14M14M14M5M0M0M0M0M0M0M0M0M0M0M0M0M0M0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ORKA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue—$0M$0M$0M$0M$0M—$0M
Gross Profit$0M$0M$0M—$0M$0M$0M$0M
Gross Margin %————————
Operating Income (EBIT)($50M)($36M)($34M)($34M)($28M)($25M)($38M)($29M)
Operating Margin %————————
Net Income($41M)($32M)($30M)($30M)($25M)($21M)($33M)($29M)
Net Margin %————————
EBITDA($50M)($32M)($30M)($30M)($25M)($21M)($37M)($28M)
Earnings Per Share (EPS)$-0.66$-0.58$-0.54$-0.69$-0.58$-0.50$-1.99$-1.91
Shares Outstanding (M)63M55M54M44M42M42M17M15M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ORKA Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-31
Cash from Operations (CFO)($101M)($88M)($58M)($11M)($19M)($8M)($5M)($8M)($17M)($15M)($11M)($9M)($5M)($4M)($7M)($8M)($42M)($18M)($46M)($37M)($59M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$1M$0M$2M$3M
Free Cash Flow (FCF)($101M)($88M)($58M)($11M)($19M)($8M)($5M)($8M)($17M)($15M)($11M)($9M)($5M)($4M)($7M)($8M)($42M)($20M)($46M)($40M)($62M)
FCF Margin %——————————————————-98.9%-1016.0%—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ORKA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($33M)($24M)($23M)($22M)($23M)($21M)($19M)($35M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($33M)($24M)($23M)($22M)($23M)($21M)($19M)($35M)
FCF Margin %————————

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ORKA Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$1.1B$489M$396M$38M$43M$55M$50M$9M$7M$12M$25M$40M$16M$17M$3M$7M$8M$9M$11M$121M$184M
Cash & Cash Equivalents$268M$47M$62M$37M$42M$53M$49M$8M$7M$9M$7M$39M$15M$17M$3M$6M$7M$8M$8M$32M$60M
Total Liabilities$25M$17M$14M$1M$1M$4M$4M$1M$1M$2M$2M$2M$1M$2M$0M$1M$1M$2M$16M$53M$115M
Total Debt (Short + Long-Term)$1M$1M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$12M$0M$4M
Total Shareholders' Equity$1.1B$472M$382M$37M$42M$51M$47M$8M$6M$10M$22M$38M$15M$16M$3M$6M$7M$7M($5M)$68M$70M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ORKA viewer.

Other Companies in BIOTECHNOLOGY

← ORISSAMINEAll “O” companiesORKLAINDIA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.